DE69739286D1 - Rekombinationsunfähige retrovirale vektoren - Google Patents

Rekombinationsunfähige retrovirale vektoren

Info

Publication number
DE69739286D1
DE69739286D1 DE69739286T DE69739286T DE69739286D1 DE 69739286 D1 DE69739286 D1 DE 69739286D1 DE 69739286 T DE69739286 T DE 69739286T DE 69739286 T DE69739286 T DE 69739286T DE 69739286 D1 DE69739286 D1 DE 69739286D1
Authority
DE
Germany
Prior art keywords
pol
expression cassettes
env
ltr
gag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739286T
Other languages
English (en)
Inventor
James G Respess
Nicholas J Depolo
Sunil Chada
Sybille Sauter
Mordechai Bodner
David A Driver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Application granted granted Critical
Publication of DE69739286D1 publication Critical patent/DE69739286D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
DE69739286T 1996-05-06 1997-05-05 Rekombinationsunfähige retrovirale vektoren Expired - Lifetime DE69739286D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64341196A 1996-05-06 1996-05-06
US72132796A 1996-09-26 1996-09-26
PCT/US1997/007697 WO1997042338A1 (en) 1996-05-06 1997-05-05 Crossless retroviral vectors

Publications (1)

Publication Number Publication Date
DE69739286D1 true DE69739286D1 (de) 2009-04-16

Family

ID=27094254

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739286T Expired - Lifetime DE69739286D1 (de) 1996-05-06 1997-05-05 Rekombinationsunfähige retrovirale vektoren

Country Status (5)

Country Link
EP (1) EP0953052B1 (de)
AT (1) ATE424463T1 (de)
AU (1) AU2998597A (de)
DE (1) DE69739286D1 (de)
WO (1) WO1997042338A1 (de)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001517433A (ja) 1997-09-24 2001-10-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非霊長類レンチウイルスベクターおよびパッケージングシステム
WO1999036511A2 (en) * 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
ATE452982T1 (de) * 1998-07-10 2010-01-15 Univ Paris Curie Verfahren zur verabreichng von nukleinsäuren in zellen in vitro oder ex vivo
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
DE60134275D1 (de) 2000-06-15 2008-07-10 Novartis Vaccines & Diagnostic Polynukleotide zur bestimmung von kolonkrebs
CA2430379A1 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
DE60236212D1 (de) 2001-11-09 2010-06-10 Univ Georgetown Neue isoform des gefässendothelzell wachstumshemmers (vegi)
CA2472282A1 (en) 2002-01-08 2003-07-17 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
CA2479730A1 (en) 2002-03-21 2003-10-02 Sagres Discovery, Inc. Novel compositions and methods in cancer
EP1532161B1 (de) 2002-06-13 2012-02-15 Novartis Vaccines and Diagnostics, Inc. Vektoren zur expression von hml-2-polypeptiden
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP2058408A3 (de) 2003-02-14 2009-09-09 Sagres Discovery, Inc. Therapeutische GPCR-Targets für Karzinome
CA2516454A1 (en) 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
WO2005062955A2 (en) 2003-12-23 2005-07-14 Rinat Neuroscience Corp. Agonist anti-trkc antibodies and methods using same
TWI367101B (en) 2004-04-07 2012-07-01 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
TR201808440T4 (tr) 2004-07-09 2018-07-23 Henry M Jackson Found Advancement Military Medicine Inc Hendra ve nipah virüsü G glikoproteininin çözünebilen formları.
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
CA2575663C (en) 2004-07-30 2013-04-23 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
EP1858919B1 (de) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immungene von uropathogenen escherichia coli
EP2062591A1 (de) 2005-04-07 2009-05-27 Novartis Vaccines and Diagnostics, Inc. CACNA1E in der Krebsdiagnose-Erkennung und -Behandlung
WO2006110585A2 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes (prlr)
WO2007014169A2 (en) 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-cd26 antibodies and methods of use thereof
CA2626120C (en) 2005-11-14 2012-12-04 Rinat Neuroscience Corp. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US7935342B2 (en) 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
SG172684A1 (en) 2006-06-07 2011-07-28 Bioalliance Cv Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
WO2008124176A2 (en) 2007-04-10 2008-10-16 The Administrators Of The Tulane Educational Fund Soluble and membrane-anchored forms of lassa virus subunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN102216329A (zh) 2007-12-17 2011-10-12 辉瑞有限公司 间质性膀胱炎的治疗
ES2550757T3 (es) 2007-12-18 2015-11-12 Bioalliance C.V. Anticuerpos que reconocen un epítopo que contiene carbohidratos en CD43 y ACE expresados en células cancerosas y métodos de uso de los mismos
EP3023502A1 (de) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
JP2012519482A (ja) 2009-03-06 2012-08-30 ノバルティス アーゲー クラミジア抗原
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
SI2510947T1 (sl) 2009-04-14 2016-05-31 Glaxosmithkline Biologicals S.A. Sestavki za imunizacijo proti Staphylococcus aureus
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
SG177533A1 (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
CN102770443A (zh) 2009-07-16 2012-11-07 诺华有限公司 脱毒大肠杆菌免疫原
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
MX2012010481A (es) 2010-03-11 2012-10-09 Rinat Neuroscience Corp Anticuerpos con union de antigenos dependiente del ph.
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
AU2012335205A1 (en) 2011-11-11 2014-05-29 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
MX2014007644A (es) 2011-12-22 2014-09-26 Rinat Neuroscience Corp Anticuerpos antagonistas del receptor de hormona de crecimiento humana y metodos para su uso.
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
US20150191702A1 (en) 2012-07-02 2015-07-09 Commonwealth Scientific And Industrial Research Organization Paramyxovirus and Methods of Use
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
BR112015010722A2 (pt) 2012-11-09 2017-08-22 Pfizer Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos
CA3208188A1 (en) 2013-03-15 2014-09-25 Takeda Pharmaceutical Company Limited Anti-plasma kallikrein antibodies
KR20160005749A (ko) 2013-05-07 2016-01-15 리나트 뉴로사이언스 코프. 항-글루카곤 수용체 항체 및 이의 사용 방법
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
BR112016002008B1 (pt) 2013-08-02 2021-06-22 Pfizer Inc. Anticorpos anti-cxcr4, seu uso, conjugado anticorpo-fármaco e composição farmacêutica
NZ719092A (en) 2013-11-13 2022-05-27 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
LT3119431T (lt) 2014-03-21 2024-03-12 Teva Pharmaceuticals International Gmbh Antagonistiniai antikūnai, nukreipti prieš peptidą, susijusį su kalcitonino genu, ir jų panaudojimo būdai
EP3139955B1 (de) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusionsproteine zur behandlung von krebs und zugehörige verfahren
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
DK3283106T3 (da) 2015-04-13 2022-01-10 Pfizer Terapeutiske antistoffer og anvendelser deraf
EA201890340A1 (ru) 2015-07-21 2018-09-28 Дайэкс Корп. Моноклональное антитело-ингибитор фактора xiia
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
EP3325010B1 (de) 2015-07-23 2023-06-21 The Regents of The University of California Antikörper gegen gerinnungsfaktor xia und verwendungen davon
SG10201912817YA (en) 2015-08-19 2020-02-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
MX2018003196A (es) 2015-09-15 2019-05-16 Scholar Rock Inc Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
WO2017070561A1 (en) 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
EP3397276A4 (de) 2015-12-30 2019-12-18 Kodiak Sciences Inc. Antikörper und konjugate davon
ES2904593T3 (es) 2016-01-21 2022-04-05 Pfizer Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
US11198735B2 (en) 2017-03-03 2021-12-14 Rinat Neuroscience Corp. Anti-GITR antibodies and methods of use thereof
EP3596206A1 (de) 2017-03-16 2020-01-22 Pfizer Inc Tyrosinprototrophie
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
KR102356984B1 (ko) 2017-06-02 2022-01-28 화이자 인코포레이티드 Flt3에 특이적인 항체 및 이의 용도
US20180357361A1 (en) 2017-06-13 2018-12-13 Feliks Frenkel Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
EP3692370A2 (de) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Artikel und verfahren zur personalisierten krebstherapie
PE20211299A1 (es) 2018-02-01 2021-07-20 Pfizer Receptores de antigeno quimericos dirigidos a cd70
PE20210708A1 (es) 2018-02-01 2021-04-16 Pfizer Anticuerpos especificos para cd70 y sus usos
KR20200128116A (ko) 2018-02-28 2020-11-11 화이자 인코포레이티드 Il-15 변이체 및 이의 용도
CA3100829A1 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
CA3100828A1 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for cd3 and uses thereof
CA3146077A1 (en) 2019-07-03 2021-02-18 Bostongene Corporation Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
EP4041308A1 (de) 2019-10-07 2022-08-17 University of Virginia Patent Foundation Modulation von lymphgefässen bei neurologischen erkrankungen
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
EP4041773A1 (de) 2019-10-11 2022-08-17 Beth Israel Deaconess Medical Center, Inc. Anti-tn-antikörper und verwendungen davon
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021224850A1 (en) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
AU2021308586A1 (en) 2020-07-17 2023-03-02 Pfizer Inc. Therapeutic antibodies and their uses
US20230287455A1 (en) 2020-07-30 2023-09-14 Pfizer Inc. Cells Having Gene Duplications and Uses Thereof
US20240029829A1 (en) 2020-12-04 2024-01-25 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022232615A1 (en) 2021-04-29 2022-11-03 Bostongene Corporation Machine learning techniques for estimating tumor cell expression complex tumor tissue
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
WO2023147177A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3284693A (en) 1963-05-10 1966-11-08 Lim James Method and device to increase the voltage of a direct current voltage source
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
CA1315719C (en) * 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
EP1285967A3 (de) * 1990-09-21 2005-03-02 Chiron Corporation Humanische Retroviren- Packaging Zellinie
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
CA2158977A1 (en) * 1994-05-09 1995-11-10 James G. Respess Retroviral vectors having a reduced recombination rate
DE69520496T2 (de) * 1994-05-13 2001-07-12 Chiron Corp Verfahren und zusammensetzungen als vehikel zur zielgerichtete einbringen von genen
US5698446A (en) * 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus

Also Published As

Publication number Publication date
ATE424463T1 (de) 2009-03-15
EP0953052A1 (de) 1999-11-03
WO1997042338A1 (en) 1997-11-13
AU2998597A (en) 1997-11-26
EP0953052B1 (de) 2009-03-04

Similar Documents

Publication Publication Date Title
DE69739286D1 (de) Rekombinationsunfähige retrovirale vektoren
ATE381624T1 (de) Retrovirale vektoren mit verminderter rekombinationsrate
GB2369121A (en) Producer cell for the production of retroviral vectors
GB2331522A (en) Lentiviral vectors
MX163418B (es) Composiciones de pasta dental
CY1107760T1 (el) Κυτταρα φακοϊικου εγκλεισμου
TR200000338T2 (tr) Polietilen'in hazırlanmasına mahsus bir yöntem.
NO982987D0 (no) Amidinoproteasehemmere
BR9912392A (pt) Benzoilcicloexanodionas substituìdas
DE69405230T2 (de) Prostaglandinrezeptor ep1 kodierende dna
NO981393D0 (no) Guanidinoproteasehemmere
FR2730735B1 (fr) Sequences amplificatrices, vecteurs portant ces sequences et leurs utilisations dans des compositions pour l'expression de sequences nucleotidiques dans des cellules transfectees, applications therapeutiques et vaccinales
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
ATE323776T1 (de) Retrovirale vektoren zur expression in embryonalen zellen
CA2258802A1 (fr) Conjugues d'un oligonucleotide/polymere conducteur electronique avec une molecule d'interet, et leurs utilisations
ES2157435T3 (es) Particulas retroviricas pseudotipadas.
BR9801143A (pt) Copolìmeros de bloco de siloxano inovativos com espaçamento rìgidos e uso dos mesmos.
AR020076A1 (es) LíNEA CELULAR DE EMPAQUETAMIENTO DE RETROVIRUS ANFOTRoPICO, PROCESO PARA SU PRODUCCIoN, Y PROCESO PARA LA PRODUCCIoN DE UN VECTOR RETROVIRAL MEDIANTE LA MISMA.
NO20002013D0 (no) Suspensjonsforpakningscellelinjer for retrovirusvektorer
DE69834422D1 (de) Klonierungsverfahren durch multiple verdauung
HUP0001058A2 (hu) 5-Hidroxi-metil-2-amino-tetralinok mint szív-érrendszerre ható szerek, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
WO2000071737A3 (en) Improved retroviral production by inhibition of the enveloppe cell receptor
ATE251611T1 (de) Additionsreaktion mit asymmetrischem konjugat
RO92624B1 (ro) Procedeu de polimerizare a stirenului

Legal Events

Date Code Title Description
8364 No opposition during term of opposition